guest ::
| Home > Publications database > Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study > print |
| Home > Publications database > Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study > print |
| 001 | 916865 | ||
| 005 | 20231027114351.0 | ||
| 024 | 7 | _ | |a 10.1002/alz.12696 |2 doi |
| 024 | 7 | _ | |a 1552-5260 |2 ISSN |
| 024 | 7 | _ | |a 1552-5279 |2 ISSN |
| 024 | 7 | _ | |a 2128/34203 |2 Handle |
| 024 | 7 | _ | |a 35715930 |2 pmid |
| 024 | 7 | _ | |a WOS:000812481000001 |2 WOS |
| 037 | _ | _ | |a FZJ-2023-00157 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Altomare, Daniele |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management Study |
| 260 | _ | _ | |a Hoboken, NJ |c 2023 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1679986881_26965 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Introduction: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features and discuss the representativeness of the cohort.Methods: Participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice.Results: A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms.Discussion: The features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.Keywords: Alzheimer's; PET; amyloid; dementia; memory clinic population; mild cognitive impairment; subjective cognitive decline. |
| 536 | _ | _ | |a 5252 - Brain Dysfunction and Plasticity (POF4-525) |0 G:(DE-HGF)POF4-5252 |c POF4-525 |f POF IV |x 0 |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Collij, Lyduine |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Caprioglio, Camilla |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Scheltens, Philip |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a van Berckel, Bart N. M. |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Alves, Isadora Lopes |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Berkhof, Johannes |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a de Gier, Yvonne |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Garibotto, Valentina |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Moro, Christian |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Poitrine, Léa |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Delrieu, Julien |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Payoux, Pierre |0 P:(DE-HGF)0 |b 12 |
| 700 | 1 | _ | |a Saint-Aubert, Laure |0 P:(DE-HGF)0 |b 13 |
| 700 | 1 | _ | |a Molinuevo, José Luis |0 P:(DE-HGF)0 |b 14 |
| 700 | 1 | _ | |a Grau-Rivera, Oriol |0 P:(DE-HGF)0 |b 15 |
| 700 | 1 | _ | |a Gispert, Juan-Domingo |0 P:(DE-HGF)0 |b 16 |
| 700 | 1 | _ | |a Minguillón, Carolina |0 P:(DE-HGF)0 |b 17 |
| 700 | 1 | _ | |a Fauria, Karine |0 P:(DE-HGF)0 |b 18 |
| 700 | 1 | _ | |a Sanchez, Marta Felez |0 P:(DE-HGF)0 |b 19 |
| 700 | 1 | _ | |a Rădoi, Andreea |0 P:(DE-HGF)0 |b 20 |
| 700 | 1 | _ | |a Drzezga, Alexander |0 P:(DE-Juel1)177611 |b 21 |
| 700 | 1 | _ | |a Jessen, Frank |0 P:(DE-HGF)0 |b 22 |
| 700 | 1 | _ | |a Escher, Claus |0 P:(DE-HGF)0 |b 23 |
| 700 | 1 | _ | |a Zeyen, Philip |0 P:(DE-HGF)0 |b 24 |
| 700 | 1 | _ | |a Nordberg, Agneta |0 P:(DE-HGF)0 |b 25 |
| 700 | 1 | _ | |a Savitcheva, Irina |0 P:(DE-HGF)0 |b 26 |
| 700 | 1 | _ | |a Jelic, Vesna |0 P:(DE-HGF)0 |b 27 |
| 700 | 1 | _ | |a Walker, Zuzana |0 P:(DE-HGF)0 |b 28 |
| 700 | 1 | _ | |a Lee, Ho-Yun |0 P:(DE-HGF)0 |b 29 |
| 700 | 1 | _ | |a Lee, Lean |0 P:(DE-HGF)0 |b 30 |
| 700 | 1 | _ | |a Demonet, Jean-François |0 P:(DE-HGF)0 |b 31 |
| 700 | 1 | _ | |a Plaza Wuthrich, Sonia |0 P:(DE-HGF)0 |b 32 |
| 700 | 1 | _ | |a Gismondi, Rossella |0 P:(DE-HGF)0 |b 33 |
| 700 | 1 | _ | |a Farrar, Gill |0 P:(DE-HGF)0 |b 34 |
| 700 | 1 | _ | |a Barkhof, Frederik |0 P:(DE-HGF)0 |b 35 |
| 700 | 1 | _ | |a Stephens, Andrew W. |0 P:(DE-HGF)0 |b 36 |
| 700 | 1 | _ | |a Frisoni, Giovanni B. |0 P:(DE-HGF)0 |b 37 |
| 700 | 1 | _ | |a Consortium, AMYPAD |0 P:(DE-HGF)0 |b 38 |
| 773 | _ | _ | |a 10.1002/alz.12696 |g p. alz.12696 |0 PERI:(DE-600)2201940-6 |n 3 |p 844-856 |t Alzheimer's and dementia |v 19 |y 2023 |x 1552-5260 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/916865/files/Alzheimer%20s%20Dementia%20-%202022%20-%20Altomare%20-%20Description%20of%20a%20European%20memory%20clinic%20cohort%20undergoing%20amyloid%E2%80%90PET%20The.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:916865 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 21 |6 P:(DE-Juel1)177611 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5252 |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 1 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-11 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0 |0 LIC:(DE-HGF)CCBYNC4 |2 HGFVOC |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2022-11-11 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-11 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-25 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b ALZHEIMERS DEMENT : 2022 |d 2023-10-25 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|